Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on April 8, 2008
JNCI Journal of the National Cancer Institute 2008 100(8):530-532; doi:10.1093/jnci/djn119
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
100/8/530    most recent
djn119v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Hede, K.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hede, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

NEWS

Doctors Seek To Prevent Breast Cancer Recurrence by Lowering Insulin Levels

Karyn Hede

The first 150 words of the full text of this article appear below.

Even in this era of targeted molecular therapies, an old drug can sometimes provide a surprising new benefit. A case in point, the diabetes drug metformin is emerging as a potential treatment for breast cancer on the basis of evidence that cancer patients with lower insulin levels have better outcomes. But using a diabetes drug to lower insulin levels in patients who are not diabetic has caused concern among some researchers, who say that doctors first need to know more about how metformin works in the oncology setting.

First isolated as an active ingredient in the medieval herbal remedy goat's rue, metformin has been used to treat type II diabetes for more than 50 years. The U.S. Food and Drug Administration approved its use in the United States in 1995, and it is now the most prescribed drug for type II diabetes, the adult-onset form of the disease that accounts . . . [Full Text of this Article]

AMP Kinase Pathway

Cautionary Note


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?